Tags

Type your tag names separated by a space and hit enter

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Case Rep Gastroenterol. 2021 May-Aug; 15(2):657-661.CR

Abstract

Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis to the medication after the second dose. A drug desensitization protocol was created by the allergy team leading to successful administration of both intravenous and then subcutaneous ustekinumab. As monoclonal agents become mainstays of therapy for inflammatory conditions, there are increased reports of allergic reactions. Prior reports and protocols of ustekinumab desensitization have not been reported. This case report highlights successful desensitization to ustekinumab as well as the importance of a multidisciplinary approach to addressing treatment needs of patients who develop life-threatening reactions to such medications.

Authors+Show Affiliations

Division of Allergy and Immunology, Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.Division of Allergy and Immunology, Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. Division of Allergy and Immunology, Department of Medicine and Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

34720823

Citation

Cohen, Barrie, et al. "Successful Drug Desensitization to Ustekinumab in a Patient With Crohn's Disease." Case Reports in Gastroenterology, vol. 15, no. 2, 2021, pp. 657-661.
Cohen B, Tomer G, Gavrilova T. Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease. Case Rep Gastroenterol. 2021;15(2):657-661.
Cohen, B., Tomer, G., & Gavrilova, T. (2021). Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease. Case Reports in Gastroenterology, 15(2), 657-661. https://doi.org/10.1159/000516318
Cohen B, Tomer G, Gavrilova T. Successful Drug Desensitization to Ustekinumab in a Patient With Crohn's Disease. Case Rep Gastroenterol. 2021 May-Aug;15(2):657-661. PubMed PMID: 34720823.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease. AU - Cohen,Barrie, AU - Tomer,Gitit, AU - Gavrilova,Tatyana, Y1 - 2021/07/20/ PY - 2021/03/09/received PY - 2021/03/19/accepted PY - 2021/11/1/entrez PY - 2021/11/2/pubmed PY - 2021/11/2/medline KW - Crohn's disease KW - Desensitization KW - Ustekinumab SP - 657 EP - 661 JF - Case reports in gastroenterology JO - Case Rep Gastroenterol VL - 15 IS - 2 N2 - Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis to the medication after the second dose. A drug desensitization protocol was created by the allergy team leading to successful administration of both intravenous and then subcutaneous ustekinumab. As monoclonal agents become mainstays of therapy for inflammatory conditions, there are increased reports of allergic reactions. Prior reports and protocols of ustekinumab desensitization have not been reported. This case report highlights successful desensitization to ustekinumab as well as the importance of a multidisciplinary approach to addressing treatment needs of patients who develop life-threatening reactions to such medications. SN - 1662-0631 UR - https://www.unboundmedicine.com/medline/citation/34720823/Successful_Drug_Desensitization_to_Ustekinumab_in_a_Patient_with_Crohn's_Disease_ L2 - https://www.karger.com?DOI=10.1159/000516318 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.